Fig. 2From: Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial – the PRODIGE 22 - ECKINOXE trialThe Tumor Regression Grade (TRG), as simplified to three categories by Ryan (19). TRG1: Major response; TRG2: Intermediate response; TRG3: No responseBack to article page